Next Article in Journal
Carbapenemase-Producing Raoultella Planticola: A Rare Cause of Pneumonia and Bacteremia
Previous Article in Journal
Prevention of Progression in Myopia: A Systematic Review
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessFeature PaperReview

Anti-Diabetic Medications for the Pharmacologic Management of NAFLD

1
Department of Medicine, Roger Williams Medical Center, Providence, RI 02908, USA
2
Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA
3
Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19129, USA
4
Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128, USA
5
Department of Medicine, Mary Imogene Bassett Hospital, Cooperstown, NY 13326, USA
6
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 750 Welch Road # 210, Stanford, CA 94304, USA
*
Author to whom correspondence should be addressed.
Diseases 2018, 6(4), 93; https://doi.org/10.3390/diseases6040093
Received: 9 August 2018 / Revised: 5 September 2018 / Accepted: 28 September 2018 / Published: 3 October 2018
  |  
PDF [222 KB, uploaded 3 October 2018]

Abstract

As a chronic disease encompassing a wide spectrum of liver-related histologic damage, nonalcoholic fatty liver disease (NAFLD) is becoming a global epidemic with significant impacts on all-cause morbidity and mortality. Insulin resistance and type 2 diabetes mellitus predispose individuals to NAFLD and related complications. Therefore, timely intervention with anti-diabetic medications may prevent and delay the development of NAFLD or have a therapeutic implication. The focus of this review is to evaluate the evidence supporting the efficacy of anti-diabetic medications in the treatment of NAFLD. While many of these anti-diabetic agents have shown to improve biochemical parameters, their effect on hepatic histology is limited. Among anti-diabetic medications, only thiazolidinediones and glucagon-like peptide-1 receptor agonists demonstrate significant improvement in hepatic histology. View Full-Text
Keywords: NAFLD; NASH; anti-diabetic medication; metformin; TZD NAFLD; NASH; anti-diabetic medication; metformin; TZD
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Cholankeril, R.; Patel, V.; Perumpail, B.J.; Yoo, E.R.; Iqbal, U.; Sallam, S.; Shah, N.D.; Kwong, W.; Kim, D.; Ahmed, A. Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. Diseases 2018, 6, 93.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top